AI Tool Comparison

Comparing as AI Medical Imaging & Diagnostics
PathAI vs Aidoc

PathAI

Aidoc

Verdict by Category

Detailed category analysis is not available for this comparison.

View PathAI View Aidoc

Detailed Comparison

Feature

PathAI

Aidoc

Pricing

EnterprisePathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division. Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development. Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.

CustomAidoc operates on enterprise contracts with hospitals and health systems — there is no published pricing or self-serve option. Pricing is customized based on hospital size, imaging volume, number of AI algorithms deployed, and integration complexity. Health systems engage through Aidoc's enterprise sales team, who assess needs, design a deployment plan, and structure a contract that typically includes implementation, onboarding, and ongoing support. Aidoc's BRIDGE framework with NVIDIA supports scalable rollout across multi-site health systems. Contact Aidoc directly at aidoc.com to request a demo or begin the enterprise procurement process.

PathAI Pros & Cons

Pros

Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
32.5M+ expert annotations — one of the world's largest pathology AI training datasets
20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
CLIA-certified lab services for biopharma clinical trial support
Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
First AI pathology company recognized as a leader in CB Insights Digital Pathology market map

Cons

Acquired by Roche in May 2026 — future product roadmap and independent operations may change
Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
No self-serve pricing or trial — all engagements are through enterprise procurement
Requires digital pathology infrastructure (scanners, storage, LIS integration)
Integration complexity for labs not yet on digital pathology workflows

Aidoc Pros & Cons

Pros

Deployed in nearly 2,000 hospitals — the most widely adopted AI radiology platform globally
60M+ patient cases analyzed annually — proven at massive scale
$534M raised — one of the best-funded medical AI companies in the world
Dozens of FDA clearances — most extensively cleared AI imaging portfolio available
PACS-agnostic — works with any existing radiology infrastructure
Gartner Cool Vendor and named in multiple industry AI leadership reports
CARE1 foundation model and BRIDGE/NVIDIA framework for next-gen AI deployment